Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The way you keep adding shares or alluding to, you must have more shares then spreadex.
If you had that much confidence you wouldn’t sliced off. People talk about de rampers potentially causing the actuall sp to go down. What about the top slicers that took a tidy profit at 13/14 ?
cashing out at that stage DID affect the sp. I would encourage everyone to check people’s history before investing in this stock. The news update didn’t tell us anything we didn’t already know.
This persons history in particular has a theme of enticing/encouragement. Do your own research and don’t listen to these people dropping in “oh I’ve topped up another 100k” . More waffle then Birdseye. Be careful people.
WFG, I have quite a few shares here, after yesterday’s RNS, it has given me the confidence to add more.
We will see many multiples of today’s sp imho.
Have a good weekend all , I’m off out for a few Chang’s.
It was positive news but nothing we didn’t already know really, Dan probably just steadying the ship just a little. Patience is the key here, switch off a little if you truly believe in your investment. Rome wasn’t built in a day and NXP001 ROW, NXP002 development and Ebers certainly won’t be built an the last 6 weeks. I’m not worried but only have 100k invested, happy with my choices DYOR
Definitely a lot of good stuff to take from the interview. No unexpected problems. When the payments come in this thing could get up and running again, may do so before!
o After the year end Nuformix announced achievement of a second pre-clinical milestone plus success in a human pharmacokinetic study triggering a total payment of £2.5m. (From today post we know payment is coming soon)
o Out-performed the current standard of care treatment, Esbriet ® (pirfenidone), in reducing fibrosis and inflammation. (NXP002)
- The deal will bring in further revenue driven by patent filings and pre-clinical outcomes. (Ebers deal) (from today's. posts we know £500k received/ was there mention of patents being applied for? If so further payments to potentially follow!)
- With validation in clinic established for our underlying technology, the subsequent de-risking of Nuformix's wider pipeline and completion of the Ebers deal collectively confirms our business model is on track to deliver significant growth in shareholder value in 2019/20.
- "With significant income due from IP licensing and collaborative development programmes in H1 2019/20 and validation of its platform in clinic, we're very excited that Nuformix is positioned well to progress multiple programmes towards patients, delivering its promise of therapeutic innovation and growth in shareholder value."
- The Group has completed several deals, generated revenues and hit important milestones within its partnerships, with further payments expected to come in H1 2019/20.
- The deal has brought in upfront revenue, with further near-term payments driven by patent filings and pre-clinical outcomes. (Ebers deal - what was the upfront revenue? £500k?)
- Combined income from the Newsummit Biopharma Licensing agreement for NXP001 and the Strategic Cannabinoid Agreement signed with Ebers is expected to generate significant income in H1 2019/20. The Group is in commercial discussions with a number of organisations regarding additional out-licensing and collaborative development opportunities which will also be revenue generating in 2019.
o After the year end Nuformix announced achievement of a second pre-clinical milestone plus success in a human pharmacokinetic study triggering a total payment of £2.5m.
o Out-performed the current standard of care treatment, Esbriet ® (pirfenidone), in reducing fibrosis and inflammation. (NXP002)
- The deal will bring in further revenue driven by patent filings and pre-clinical outcomes. (Ebers deal)
- With validation in clinic established for our underlying technology, the subsequent de-risking of Nuformix's wider pipeline and completion of the Ebers deal collectively confirms our business model is on track to deliver significant growth in shareholder value in 2019/20.
- "With significant income due from IP licensing and collaborative development programmes in H1 2019/20 and validation of its platform in clinic, we're very excited that Nuformix is positioned well to progress multiple programmes towards patients, delivering its promise of therapeutic innovation and growth in shareholder value."
- The Group has completed several deals, generated revenues and hit important milestones within its partnerships, with further payments expected to come in H1 2019/20.
- The deal has brought in upfront revenue, with further near-term payments driven by patent filings and pre-clinical outcomes. (Ebers deal - what was the upfront revenue?)
- Combined income from the Newsummit Biopharma Licensing agreement for NXP001 and the Strategic Cannabinoid Agreement signed with Ebers is expected to generate significant income in H1 2019/20. The Group is in commercial discussions with a number of organisations regarding additional out-licensing and collaborative development opportunities which will also be revenue generating in 2019.